LAB+4.32%
Earnings
IDEXX (IDXX) Surpasses Expectations with $902 Million in Q4 Revenue and a 13% EPS Increase
IDEXX Laboratories, Inc. (NASDAQ: IDXX) reported a robust fourth quarter of 2023 with revenues reaching $902 million.
Editorial disclosureRead more
All reviews, research, news and assessments of any kind on The Tokenist are compiled using a strict editorial review process by our editorial team. Neither our writers nor our editors receive direct compensation of any kind to publish information on tokenist.com. Our company, Tokenist Media LLC, is community supported and may receive a small commission when you purchase products or services through links on our website. Click here for a full list of our partners and an in-depth explanation on how we get paid.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, reported a strong performance in the fourth quarter of 2023, underlining its continued growth and operational excellence.
IDEXX Laboratories announced a revenue of $901.6 million for the fourth quarter of 2023, marking a 9% increase compared to the same period in the previous year. This growth was driven primarily by a 10% rise in Companion Animal Group (“CAG”) Diagnostics recurring revenue, supported by high-quality placements of CAG Diagnostics capital instruments, strong customer retention, new business gains, and net price realization.
Earnings per share (EPS) for the quarter were $2.32, up 13% from the prior year, reflecting the company’s operational efficiency and strategic investments in growth. The strong quarter was further highlighted by a 10% organic growth in CAG Diagnostics recurring revenue, emphasizing IDEXX’s ability to expand its market presence and leverage its innovative diagnostic solutions.
IDEXX Labs Outperforms in Q4 with $2.32 EPS
The company’s fourth-quarter performance exceeded market expectations, with analysts projecting an EPS of $2.12 and revenue of $891.08 million. The actual revenue of $902 million and EPS of $2.32 not only surpassed these projections but also showcased IDEXX’s robust growth trajectory and ability to outperform in a competitive landscape. This outperformance is a testament to IDEXX’s strategic initiatives and its focus on delivering comprehensive pet healthcare solutions.
Guidance for the Future
For 2024, IDEXX has set a revenue guidance range of $3,930 million to $4,040 million, reflecting an anticipated growth of 7.5% to 10.5%. This outlook is supported by expected CAG Diagnostics recurring revenue growth of 7.5% to 10.5%, both reported and on an organic basis. The EPS guidance for 2024 is set at $10.84 to $11.33, indicating an 8% to 13% increase. This guidance underscores the company’s confidence in its growth drivers and its commitment to sustaining momentum through innovations, such as the launch of the new slide-free cellular analyzer, IDEXX inVue Dx™, targeted for late 2024.
Disclaimer: The author does not hold or have a position in any securities discussed in the article.
Tim Fries
Tim Fries is the cofounder of The Tokenist. He has a B. Sc. in Mechanical Engineering from the University of Michigan, and an MBA from the University of Chicago Booth School of Business. Tim served as a Senior Associate on the investment team at RW Baird's US Private Equity division, and is also the co-founder of Protective Technologies Capital, an investment firm specializing in sensing, protection and control solutions.
